



HEAD OF MEDICAL COMMUNICATIONS

Kala is an emerging pharmaceutical company on the verge of commercialization. We are seeking an experienced Medical Affairs professional to join a growing and dynamic organization. This is an opportunity for the right individual to come onboard and strategically communicate our incredible science to the world. Come join an experienced and highly motivated team!

Key Responsibilities for this role will include:

- Develop and implement strategies for communication of key scientific and medical information to the eye care community.
- Develop and implement strategies for medical education efforts (e.g., disease state education, continuing medical education).
- Develop and implement key scientific publication strategies to effectively communicate key clinical and nonclinical results with Kala products and product candidates.
- Interface with key eye care organizations to elevate Kala exposure with eye care professionals.

Our ideal candidate will have:

- Masters required, PhD or PharmD preferred.
- 5-10 years of medical communications experience.
- Aptitude to work in a collaborative team environment.
- Impeccable communication skills.
- Ability to handle confidential information.
- Must be able to anticipate needs, be proactive and exercise independent decision-making.

If you are interested in applying for this role, please send your resume directly to Careers@Kalarx.com and include the job title in your subject line.

About Us:

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYSTM(KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which we have submitted a NDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease, which is currently in Phase 3 clinical development.